Identification of benzothiazole-rhodanine derivatives as α-amylase and α-glucosidase inhibitors: Design, synthesis, in silico, and in vitro analysis

J Mol Recognit. 2022 Aug;35(8):e2959. doi: 10.1002/jmr.2959. Epub 2022 Apr 21.

Abstract

A novel series of benzothiazole-rhodanine derivatives (A1-A10) were designed and synthesized, with the aim of developing possible antidiabetic agents and the spectral characterization of these compounds was done using infrared spectroscopy (IR), proton-nuclear magnetic resonance (1 H-NMR), carbon-nuclear magnetic resonance (C13 -NMR), and high resolution mass spectroscopy (HR-MS) techniques. In vitro hypoglycemic potential of the compounds was evaluated by performing α-amylase and α-glucosidase enzyme inhibitory assays. In addition, these compounds were subjected to in silico analysis. Based on the results, compounds A5, A6, and A9 displayed good activity in comparison with the standard acarbose. Based on Lineweaver-Burk plots, it was concluded that compounds A5 and A9 displayed competitive type of enzyme inhibition. Molecular dynamic simulations were conducted to evaluate the stability of the ligand-protein complex by the calculation of the root mean square deviation, root means square fluctuation, and solvent accessible surface area.

Keywords: diabetes mellitus; in silico analysis; molecular dynamics; pharmacophore; rhodanines.

MeSH terms

  • Benzothiazoles / pharmacology
  • Glycoside Hydrolase Inhibitors* / chemistry
  • Glycoside Hydrolase Inhibitors* / pharmacology
  • Hypoglycemic Agents / chemistry
  • Molecular Docking Simulation
  • Rhodanine* / pharmacology
  • Structure-Activity Relationship
  • alpha-Amylases / metabolism
  • alpha-Glucosidases / chemistry
  • alpha-Glucosidases / metabolism

Substances

  • Benzothiazoles
  • Glycoside Hydrolase Inhibitors
  • Hypoglycemic Agents
  • Rhodanine
  • alpha-Amylases
  • alpha-Glucosidases